Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (131-140 of 280) with videos related to

Pageof 28
Sort By:
Cancer Science|February 7, 2016
Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityGary K Schwartz, Mark A Dickson, Patricia M LoRusso, et al.
Investigational New Drugs|July 30, 1999
Preclinical antitumor activity of XK469 (NSC 656889)P M LoRusso, R Parchment, L Demchik, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 3, 2012
Clinical impact of HSV-1 detection in the lower respiratory tract from hospitalized adult patientsC Costa, F Sidoti, A Saldan, et al.
Investigational New Drugs|July 30, 2018
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumorsKathleen N Moore, Johanna C Bendell, Patricia M LoRusso, et al.
Investigational New Drugs|November 15, 2006
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitorAmin M Alousi, Ramesh Boinpally, Richard Wiegand, et al.
Il Giornale Di Chirurgia|April 3, 2014
A rare case of necrotic thymomaA De Palma, V Pagliarulo, M Lorusso, et al.
Brain, Behavior, and Immunity|June 8, 2025
Prenatal poly(I:C) exposure, rather than altered maternal care, causes offspring behavioural and cognitive deficits in a rat model of neurodevelopmental disordersHarry G Potter, Rebecca M Woods, Jarred M Lorusso, et al.
Investigational New Drugs|April 9, 2001
Chronic oral administration of CI-994: a phase 1 studyS Prakash, B J Foster, M Meyer, et al.
Biomolecules|March 29, 2023
Maternal Immune Activation Induces Adolescent Cognitive Deficits Preceded by Developmental Perturbations in Cortical Reelin SignallingRebecca M Woods, Jarred M Lorusso, Isabella Harris, et al.
British Journal of Cancer|May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)G K Schwartz, P M LoRusso, M A Dickson, et al.
Pageof 28

Showing results (131-140 of 280) with videos related to

Sort By:
Pageof 28
Cancer Science|February 7, 2016
Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityGary K Schwartz, Mark A Dickson, Patricia M LoRusso, et al.
Investigational New Drugs|July 30, 1999
Preclinical antitumor activity of XK469 (NSC 656889)P M LoRusso, R Parchment, L Demchik, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 3, 2012
Clinical impact of HSV-1 detection in the lower respiratory tract from hospitalized adult patientsC Costa, F Sidoti, A Saldan, et al.
Investigational New Drugs|July 30, 2018
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumorsKathleen N Moore, Johanna C Bendell, Patricia M LoRusso, et al.
Investigational New Drugs|November 15, 2006
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitorAmin M Alousi, Ramesh Boinpally, Richard Wiegand, et al.
Il Giornale Di Chirurgia|April 3, 2014
A rare case of necrotic thymomaA De Palma, V Pagliarulo, M Lorusso, et al.
Brain, Behavior, and Immunity|June 8, 2025
Prenatal poly(I:C) exposure, rather than altered maternal care, causes offspring behavioural and cognitive deficits in a rat model of neurodevelopmental disordersHarry G Potter, Rebecca M Woods, Jarred M Lorusso, et al.
Investigational New Drugs|April 9, 2001
Chronic oral administration of CI-994: a phase 1 studyS Prakash, B J Foster, M Meyer, et al.
Biomolecules|March 29, 2023
Maternal Immune Activation Induces Adolescent Cognitive Deficits Preceded by Developmental Perturbations in Cortical Reelin SignallingRebecca M Woods, Jarred M Lorusso, Isabella Harris, et al.
British Journal of Cancer|May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)G K Schwartz, P M LoRusso, M A Dickson, et al.
Pageof 28